BEST-NMOSD: Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD (clinicaltrials.gov) - Sep 25, 2026 - P4 | N=540 | Recruiting | Sponsor: Massachusetts General Hospital | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Rare Diseases
|